MedTrace Logo

Residual Inflammation and Plaque Progression Long-term Evaluation

NCT04073810 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-07-19

No results posted yet for this study

Summary

Inflammation drives atherosclerotic plaque rupture triggering most acute coronary syndromes. Despite advances in diagnosis and management of atherosclerosis, patients with myocardial infarction (MI) remain at increased risk of recurrent events. The RIPPLE study aims to examine the relationship between residual coronary inflammation detected by 68Ga-DOTATATE PET in patients treated for MI to long-term plaque progression measured by CT coronary angiography (CTCA). The association between infarct-related myocardial 68Ga-DOTATATE PET and myocardial function and viability will also be assessed.

Conditions

Interventions

DIAGNOSTIC_TEST

PET imaging

Coronary 68Ga-DOTATATE PET-MRI or PET-CT at baseline and 3 months

DIAGNOSTIC_TEST

Coronary CT angiography

CTCA at baseline and 2 years

DIAGNOSTIC_TEST

Cardiac MRI

Cardiac MRI at 1 year

Sponsors & Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

    collaborator OTHER

  • Wellcome Trust

    collaborator OTHER

  • University of Cambridge

    lead OTHER

Principal Investigators

  • Jason M Tarkin, MBBS PhD · University of Cambridge

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2024-12-01
Completion
2025-04-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04073810 on ClinicalTrials.gov